Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells.
Journal Information
Full Title: Oncoimmunology
Abbreviation: Oncoimmunology
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Allergy and Immunology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure statement Mads Hald Andersen is named as an inventor on various patent applications relating to therapeutic uses of arginase peptides. These patent applications are assigned to the company IO Biotech ApS, which is developing immune-modulating cancer treatments. Mads Hald Andersen is founder, shareholder and advisor of IO Biotech ApS. Evelina Martinenaite is an employee at IO Biotech ApS. The other authors declare “no conflict of interest”."
"We would like to thank Merete Jonassen, Anette Højgaard Andersen and Tina Seremet for excellent technical assistance. This work was supported by Herlev and Gentofte Hospital, and through a research funding agreement between IO Biotech ApS and National Center for Cancer Immune Therapy (CCIT-DK)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025